Long-term outcomes after treatment of in-stent restenosis using the Absorb everolimus-eluting bioresorbable scaffold
Background Early studies evaluating the performance of bioresorbable scaffold (BRS) Absorb in in-stent restenosis (ISR) lesions indicated promising short-term to mid-term outcomes.Aims To evaluate long-term outcomes (up to 5 years) of patients with ISR treated with the Absorb BRS.Methods We did an o...
Saved in:
| Main Authors: | Stefan Toggweiler, Matthias Bossard, Florim Cuculi, Federico Moccetti, Mathias Wolfrum, Richard Kobza, Adrian Attinger-Toller, Mehdi Madanchi, Giacomo Maria Cioffi, Thomas Seiler, Luca Vercelli, Philipp Burkart |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2021-12-01
|
| Series: | Open Heart |
| Online Access: | https://openheart.bmj.com/content/8/2/e001776.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Stent Fracture after Everolimus-Eluting Stent Implantation
by: Ali S. Almasood, et al.
Published: (2011-01-01) -
Midterm Clinical Impacts of Biodegradable Polymer Everolimus-Eluting Stents Compared with Durable Polymer Everolimus-Eluting Stents: A 3-Year Propensity-Matched Study
by: Hiroaki Matsuda, et al.
Published: (2020-01-01) -
Outcome of Coronary Edge In-stent Restenosis Management by Restenting Versus Drug-Eluting Balloon
by: Yasser Gaber Metwally, et al.
Published: (2024-12-01) -
Absorb BRS for in-stent restenosis: the final bow before (scaffold) collapse?
by: Stéphane Cook, et al.
Published: (2021-12-01) -
The Endovascular Therapy for In-Stent Restenosis After Fluoropolymer-Based Drug-Eluting Stent Implantation in Femoropopliteal Lesions
by: Kazunori Horie, MD, et al.
Published: (2025-01-01)